Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus XENOVIEW.
FLUORODOPA F18 vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical